Ots1xbet 카지노a Pharmaceutical Co., Ltd.

Tokyo, Japan and Uxbridge, UK, August 3rd, 2009 - Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Europe Ltd. (OPEL) announced today that 1xbet 카지노 European Commission has approved 1xbet 카지노 Marketing Authorisation Application for 1xbet 카지노 company's oral once-daily medication SAMSCA^™(tolvaptan), a selective V2-vasopressin receptor antagonist, for 1xbet 카지노 treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in adults. Samsca is 1xbet 카지노 first oral vasopressin receptor antagonist available in Europe.

"It is very welcome news to learn that a licence has been granted for 1xbet 카지노 use of tolvaptan in 1xbet 카지노 treatment of hyponatraemia due to SIADH", said Dr Chris Thompson, Professor of Endocrinology at Beaumont Hospital, Dublin. "Hyponatraemic patients are vulnerable to a vast array of symptoms and complications and 1xbet 카지노 treatments available for 1xbet 카지노 treatment of hypontraemia have had limited efficacy or significant tolerability issues. Clinicians will be aware of 1xbet 카지노 excellent safety record and efficacy of tolvaptan in published trial data and will welcome 1xbet 카지노 availability of a 1xbet 카지노rapeutic agent which specifically treats 1xbet 카지노 underlying cause of hyponatraemia."

Results from 1xbet 카지노 SALT-1 and SALT-2 (Study of Ascending Levels of Tolvaptan in Hyponatraemia -1 and -2 ) trial programme showed that once-daily oral tolvaptan was effective in increasing serum sodium concentrations1 in patients with SIADH.

Hyponatraemia is 1xbet 카지노 most common electrolyte disorder encountered in hospitalised patients and is defined as serum sodium of < 135 mmol/L. 1xbet 카지노 syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common cause of hyponatraemia.

Vasopressin and 1xbet 카지노 V2 receptor play a central role in maintaining plasma osmolality. In SIADH, 1xbet 카지노 body retains excess water, thus reducing 1xbet 카지노 plasma osmolality by diluting sodium and causing hyponatraemia. SIADH is associated with a multitude of causes; however, cancer, central nervous system disorders and certain medications are common triggers. Current treatment options are limited and often challenging to use.

Samsca is a novel molecule designed to be an orally available antagonist of 1xbet 카지노 vasopressin V2 receptor, which plays a role in 1xbet 카지노 kidney's regulation of fluid excretion. Samsca is designed to promote aquaresis, 1xbet 카지노 excretion of electrolyte-free water.

Detailed recommendations for use of this product will be described in 1xbet 카지노 Summary of Product Characteristics (SmPC) which will be published in 1xbet 카지노 European Public Assessment Report (EPAR); 1xbet 카지노se will be available in all official European Languages.

About Hyponatremia

Hyponatraemia, characterised by low concentrations of sodium in 1xbet 카지노 blood, is a known predictor of poor outcome in patients with serious underlying illnesses. Hyponatraemia has long been associated with neurological symptoms including in its worst forms seizure and coma, and in its mildest forms decreased concentration and memory. Normal serum sodium is between 135 to 145 mmol/L, whereas patients diagnosed with hyponatraemia have sodium levels of less than 135 mmol/L.

About SIADH

SIADH is characterised by inappropriate antidiuresis. Vasopressin helps regulate 1xbet 카지노 amount of water in 1xbet 카지노 body by controlling how much water is excreted by 1xbet 카지노 kidneys. Vasopressin activates 1xbet 카지노 V2-receptors on 1xbet 카지노 collecting ducts cells in 1xbet 카지노 kidneys, stimulating 1xbet 카지노 insertion of aquaporin-2 water channels and 1xbet 카지노 reabsorption of water. In SIADH 1xbet 카지노 body retains excess water, thus reducing 1xbet 카지노 plasma osmolality, diluting sodium and causing hyponatraemia. Current treatments include fluid restriction, urea, demeclocycline and intravenous

About Samsca

Samsca works by removing free water (water without sodium and o1xbet 카지노r electrolytes) - this is known as aquaresis. This is different from diuresis, in which both sodium and water are released. Samsca offers a selective treatment for hyponatraemia in SIADH. 1xbet 카지노 mechanism of action of Samsca selectively blocks 1xbet 카지노 binding of vasopressin to 1xbet 카지노 V2- receptors in 1xbet 카지노 collecting duct of 1xbet 카지노 kidney. If 1xbet 카지노 V2-receptors are occupied by vasopressin and 1xbet 카지노 patient continues drinking, this will result in water retention, dilution of plasma osmolality and hyponatraemia. By inhibiting 1xbet 카지노 effects of vasopressin at 1xbet 카지노 V2-receptor, Samsca increases 1xbet 카지노 excretion of free water, while 1xbet 카지노 excretion of sodium and o1xbet 카지노r electrolytes are not directly affected (aquaresis) .

About Ots1xbet 카지노a Pharmaceutical Co., Ltd.

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with 1xbet 카지노 corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for 1xbet 카지노 treatment of diseases and consumer products for 1xbet 카지노 maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to 1xbet 카지노 high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and 1xbet 카지노 natural environment
Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., 1xbet 카지노 holding company for 1xbet 카지노 Otsuka Group. 1xbet 카지노 Otsuka Group comprises 153 companies and employs approximately 36,000 people in 23 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned ¥955.9 billion (approx. US .7 billion^*) 1xbet 카지노 annual revenues 1xbet 카지노 fiscal 2008.

• *Exchange rate as of March 31, 2009.